Cargando…

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK

Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), in contrast to membrane TWEAK and TNF, is only a weak activator of the classical NFκB pathway. We observed that soluble TWEAK was regularly more potent than TNF with respect to the induction of TNF receptor-associated factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona Arana, José Antonio, Seher, Axel, Neumann, Manfred, Lang, Isabell, Siegmund, Daniela, Wajant, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927163/
https://www.ncbi.nlm.nih.gov/pubmed/24600451
http://dx.doi.org/10.3389/fimmu.2014.00063
_version_ 1782304076578422784
author Carmona Arana, José Antonio
Seher, Axel
Neumann, Manfred
Lang, Isabell
Siegmund, Daniela
Wajant, Harald
author_facet Carmona Arana, José Antonio
Seher, Axel
Neumann, Manfred
Lang, Isabell
Siegmund, Daniela
Wajant, Harald
author_sort Carmona Arana, José Antonio
collection PubMed
description Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), in contrast to membrane TWEAK and TNF, is only a weak activator of the classical NFκB pathway. We observed that soluble TWEAK was regularly more potent than TNF with respect to the induction of TNF receptor-associated factor 1 (TRAF1), a NFκB-controlled signaling protein involved in the regulation of inflammatory signaling pathways. TNF-induced TRAF1 expression was efficiently blocked by inhibition of the classical NFκB pathway using the IKK2 inhibitor, TPCA1. In contrast, in some cell lines, TWEAK-induced TRAF1 production was only partly inhibited by TPCA1. The NEDD8-activating enzyme inhibitor MLN4924, however, which inhibits classical and alternative NFκB signaling, blocked TNF- and TWEAK-induced TRAF1 expression. This suggests that TRAF1 induction by soluble TWEAK is based on the cooperative activity of the two NFκB signaling pathways. We have previously shown that oligomerization of soluble TWEAK results in ligand complexes with membrane TWEAK-like activity. Oligomerization of soluble TWEAK showed no effect on the dose response of TRAF1 induction, but potentiated the ability of soluble TWEAK to trigger production of the classical NFκB-regulated cytokine IL8. Transfectants expressing soluble TWEAK and membrane TWEAK showed similar induction of TRAF1 while only the membrane TWEAK expressing cells robustly stimulated IL8 production. These data indicate that soluble TWEAK may efficiently induce a distinct subset of the membrane TWEAK-targeted genes and argue again for a crucial role of classical NFκB pathway-independent signaling in TWEAK-induced TRAF1 expression. Other TWEAK targets, which can be equally well induced by soluble and membrane TWEAK, remain to be identified and the relevance of the ability of soluble TWEAK to induce such a distinct subset of membrane TWEAK-targeted genes for TWEAK biology will have to be clarified in future studies.
format Online
Article
Text
id pubmed-3927163
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39271632014-03-05 TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK Carmona Arana, José Antonio Seher, Axel Neumann, Manfred Lang, Isabell Siegmund, Daniela Wajant, Harald Front Immunol Immunology Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), in contrast to membrane TWEAK and TNF, is only a weak activator of the classical NFκB pathway. We observed that soluble TWEAK was regularly more potent than TNF with respect to the induction of TNF receptor-associated factor 1 (TRAF1), a NFκB-controlled signaling protein involved in the regulation of inflammatory signaling pathways. TNF-induced TRAF1 expression was efficiently blocked by inhibition of the classical NFκB pathway using the IKK2 inhibitor, TPCA1. In contrast, in some cell lines, TWEAK-induced TRAF1 production was only partly inhibited by TPCA1. The NEDD8-activating enzyme inhibitor MLN4924, however, which inhibits classical and alternative NFκB signaling, blocked TNF- and TWEAK-induced TRAF1 expression. This suggests that TRAF1 induction by soluble TWEAK is based on the cooperative activity of the two NFκB signaling pathways. We have previously shown that oligomerization of soluble TWEAK results in ligand complexes with membrane TWEAK-like activity. Oligomerization of soluble TWEAK showed no effect on the dose response of TRAF1 induction, but potentiated the ability of soluble TWEAK to trigger production of the classical NFκB-regulated cytokine IL8. Transfectants expressing soluble TWEAK and membrane TWEAK showed similar induction of TRAF1 while only the membrane TWEAK expressing cells robustly stimulated IL8 production. These data indicate that soluble TWEAK may efficiently induce a distinct subset of the membrane TWEAK-targeted genes and argue again for a crucial role of classical NFκB pathway-independent signaling in TWEAK-induced TRAF1 expression. Other TWEAK targets, which can be equally well induced by soluble and membrane TWEAK, remain to be identified and the relevance of the ability of soluble TWEAK to induce such a distinct subset of membrane TWEAK-targeted genes for TWEAK biology will have to be clarified in future studies. Frontiers Media S.A. 2014-02-18 /pmc/articles/PMC3927163/ /pubmed/24600451 http://dx.doi.org/10.3389/fimmu.2014.00063 Text en Copyright © 2014 Carmona Arana, Seher, Neumann, Lang, Siegmund and Wajant. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Carmona Arana, José Antonio
Seher, Axel
Neumann, Manfred
Lang, Isabell
Siegmund, Daniela
Wajant, Harald
TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title_full TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title_fullStr TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title_full_unstemmed TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title_short TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK
title_sort tnf receptor-associated factor 1 is a major target of soluble tweak
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927163/
https://www.ncbi.nlm.nih.gov/pubmed/24600451
http://dx.doi.org/10.3389/fimmu.2014.00063
work_keys_str_mv AT carmonaaranajoseantonio tnfreceptorassociatedfactor1isamajortargetofsolubletweak
AT seheraxel tnfreceptorassociatedfactor1isamajortargetofsolubletweak
AT neumannmanfred tnfreceptorassociatedfactor1isamajortargetofsolubletweak
AT langisabell tnfreceptorassociatedfactor1isamajortargetofsolubletweak
AT siegmunddaniela tnfreceptorassociatedfactor1isamajortargetofsolubletweak
AT wajantharald tnfreceptorassociatedfactor1isamajortargetofsolubletweak